Seer Revenue 2021-2022 | SEER

Seer revenue from 2021 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Seer Annual Revenue
(Millions of US $)
2021 $
2020 $
Seer Quarterly Revenue
(Millions of US $)
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.468B $0.007B
Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.449B 10.01
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.298B 16.25
Biohaven Pharmaceutical Holding (BHVN) United States $10.114B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.068B 0.00
Emergent Biosolutions (EBS) United States $1.695B 7.26
Arcus Biosciences (RCUS) United States $1.307B 33.13
Myovant Sciences (MYOV) United Kingdom $0.933B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.493B 0.00
Gelesis Holdings (GLS) United States $0.348B 0.00
Zymeworks (ZYME) Canada $0.342B 0.00
Ambrx Biopharma (AMAM) United States $0.162B 0.00
Enzo Biochem (ENZ) United States $0.112B 23.00
SQZ Biotechnologies (SQZ) United States $0.094B 0.00